Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Share-based Compensation (2016 - 2025)

Coherus Oncology's Share-based Compensation history spans 13 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 56.39% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $17.0 million, down 38.98%, while the annual FY2025 figure was $17.0 million, 38.98% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.8 million at Coherus Oncology, down from $3.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $27.7 million in Q2 2021 and bottomed at $800000.0 in Q1 2021.
  • The 5-year median for Share-based Compensation is $10.0 million (2023), against an average of $9.5 million.
  • The largest annual shift saw Share-based Compensation crashed 91.63% in 2021 before it skyrocketed 1509.88% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $10.9 million in 2021, then increased by 7.13% to $11.7 million in 2022, then fell by 7.91% to $10.8 million in 2023, then plummeted by 40.88% to $6.4 million in 2024, then crashed by 56.39% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Share-based Compensation are $2.8 million (Q4 2025), $3.4 million (Q3 2025), and $5.4 million (Q2 2025).